Flubendazole inhibits glioma proliferation by G2/M cell cycle arrest and pro-apoptosis

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Flubendazole is an FDA-approved anthelmintic drug.
• Recent studies suggest Flubendazole possesses anticancer properties.
• The effect of Flubendazole on gliomas remains largely unexplored.

Purpose of the Study:

• To investigate the effects of Flubendazole on glioma cells in vitro and in vivo.
• To elucidate the underlying mechanisms of Flubendazole's action in glioma.

Main Methods:

• In vitro studies on glioma cell lines assessing proliferation, apoptosis, and migration.
• In vivo studies using xenograft models to evaluate tumor growth suppression.
• Mechanistic studies analyzing cell cycle progression, apoptosis-related protein expression (p53, Cyclin B1, p-cdc2, BCL-2).

Main Results:

• Flubendazole significantly inhibited glioma cell proliferation and induced apoptosis in vitro.
• Flubendazole suppressed tumor growth in xenograft models.
• Flubendazole treatment led to cell cycle arrest at the G2/M phase.
• Flubendazole modulated the expression of key proteins involved in cell cycle regulation and apoptosis (increased p53, decreased Cyclin B1 and p-cdc2, regulated BCL-2).
• Flubendazole did not appear to influence glioma cell migration.

Conclusions:

• Flubendazole exhibits significant anti-proliferative and pro-apoptotic effects on gliomas.
• These effects are mediated through the modulation of cell cycle progression and intrinsic apoptotic signaling pathways.
• Flubendazole represents a potential novel therapeutic agent for glioma treatment.